ECSP066494A - Composición y método para tratamiento de condiciones uro-genitales - Google Patents

Composición y método para tratamiento de condiciones uro-genitales

Info

Publication number
ECSP066494A
ECSP066494A EC2006006494A ECSP066494A ECSP066494A EC SP066494 A ECSP066494 A EC SP066494A EC 2006006494 A EC2006006494 A EC 2006006494A EC SP066494 A ECSP066494 A EC SP066494A EC SP066494 A ECSP066494 A EC SP066494A
Authority
EC
Ecuador
Prior art keywords
composition
disclosed
uro
usp
treatment
Prior art date
Application number
EC2006006494A
Other languages
English (en)
Inventor
Anna P Catania
James M Lipton
Original Assignee
Zengen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zengen Inc filed Critical Zengen Inc
Publication of ECSP066494A publication Critical patent/ECSP066494A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Polymerisation Methods In General (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención está dirigida a una composición y método para tratar condiciones uro-genitales. Una incorporación revelada es una composición farmaceútica para uso en el tratamiento de condiciones uro-genitales en la cual dicha composición comprende un regulador KPV, un primer agente conservante, un disolvente, un alcaloide, un polímero acrílico en base a un ácido, un segundo agente conservante y un agente gelatinizante. Otra incorporación de la invención que se revela es la composición que comprende un regulador CKPV (SEQ ID No. 5), API, Carbopol (r), NF, propilparaben, NF; metilparaben, NF; propilene glicol, USP; ácido edítico (EDTA), USP; 2 M solución de hidróxido de sodio (NaOH); y agua estéril para inyección, USP. También se revela los métodos e indicaciones para el uso de la composición revelada
EC2006006494A 2003-09-08 2006-04-07 Composición y método para tratamiento de condiciones uro-genitales ECSP066494A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/659,053 US7402559B2 (en) 1999-03-24 2003-09-08 Composition and method of treatment for urogenital conditions

Publications (1)

Publication Number Publication Date
ECSP066494A true ECSP066494A (es) 2006-11-24

Family

ID=34312692

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006494A ECSP066494A (es) 2003-09-08 2006-04-07 Composición y método para tratamiento de condiciones uro-genitales

Country Status (10)

Country Link
US (1) US7402559B2 (es)
EP (1) EP1667703A4 (es)
JP (1) JP2007505045A (es)
CN (1) CN1867349A (es)
AU (1) AU2004272049A1 (es)
CA (1) CA2542303A1 (es)
CR (1) CR8341A (es)
EC (1) ECSP066494A (es)
WO (1) WO2005025503A2 (es)
ZA (1) ZA200602144B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8864730B2 (en) 2005-04-12 2014-10-21 Rochester Medical Corporation Silicone rubber male external catheter with absorbent and adhesive
US20110171195A1 (en) * 2007-06-15 2011-07-14 Duke University Methods and compositions for treating urinary tract infections using agents that mimic or elevate cyclic amp
EP2217726A2 (en) * 2007-11-02 2010-08-18 Von Knebel Doeberitz, Magnus Compounds and methods associated with differential methylation of human papilloma virus genomes in epithelial cells
CN101947148A (zh) * 2010-10-11 2011-01-19 中国人民解放军第三军医大学第三附属医院 阴茎感觉增强装置
RU2452490C1 (ru) 2010-12-27 2012-06-10 Виктор Вениаминович Тец Лекарственное средство с активностью против семейства герпес-вирусов
US9707375B2 (en) 2011-03-14 2017-07-18 Rochester Medical Corporation, a subsidiary of C. R. Bard, Inc. Catheter grip and method
US10092728B2 (en) 2012-11-20 2018-10-09 Rochester Medical Corporation, a subsidiary of C.R. Bard, Inc. Sheath for securing urinary catheter
US9872969B2 (en) 2012-11-20 2018-01-23 Rochester Medical Corporation, a subsidiary of C.R. Bard, Inc. Catheter in bag without additional packaging
RU2530587C1 (ru) * 2013-06-07 2014-10-10 Виктор Вениаминович Тец Способ лечения заболеваний кожи и слизистых оболочек, вызываемых вирусами простого герпеса 1-го и 2-го типов
KR102462510B1 (ko) 2014-08-26 2022-11-01 씨. 알. 바드, 인크. 요로 카테터
RU2605602C1 (ru) 2015-09-15 2016-12-27 Общество с ограниченной ответственностью "Новые Антибиотики" Способ получения натриевой соли (2,6-дихлорфенил)амида карбопентоксисульфаниловой кислоты
JP7350722B2 (ja) 2017-09-19 2023-09-26 シー・アール・バード・インコーポレーテッド 尿カテーテルブリッジ装置、そのシステムおよび方法
CN112451654A (zh) * 2020-12-10 2021-03-09 兆科药业（广州）有限公司 司来普伐肽的新用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH422813A (de) 1960-11-17 1966-10-31 Ciba Geigy Verfahren zur Herstellung neuer Polypeptide
CH444178A (de) 1963-05-20 1967-09-30 Ciba Geigy Verfahren zur Herstellung von B-MSH
JPS5921613A (ja) 1982-07-28 1984-02-03 Takeda Chem Ind Ltd 直腸投与製剤
US5157023A (en) 1984-08-21 1992-10-20 Lipton James M Antipyretic and anti-inflammatory lys pro val compositions and method of use
US5028592A (en) 1986-08-08 1991-07-02 Lipton James M Antipyretic and anti-inflammatory peptides
US4837378A (en) * 1986-01-15 1989-06-06 Curatek Pharmaceuticals, Inc. Topical metronidazole formulations and therapeutic uses thereof
ATE84420T1 (de) 1986-02-03 1993-01-15 University Patents Inc Verfahren zur stimulierung von melanozyten durch lokales anbringen von alpha-msh-analogen, sowie zusammensetzungen.
AU604751B2 (en) 1986-08-08 1991-01-03 Board Of Regents, The University Of Texas System Anti-inflammatory peptides
JP2633369B2 (ja) 1988-03-28 1997-07-23 ブリティッシュ・テクノロジー・グループ・リミテッド ペプチド
JP2514249B2 (ja) * 1989-05-23 1996-07-10 帝人株式会社 安定化されたカルシトニン類医薬組成物
JPH0674209B2 (ja) * 1990-09-17 1994-09-21 旭化成工業株式会社 カルバ型カルシトニン類水溶液注射剤の安定化方法
DE69232586T2 (de) 1991-07-05 2002-11-28 Peptech Ltd., North Ryde Giftigkeit von tnf und lps ausschaltende peptide
JP3628713B2 (ja) 1993-06-07 2005-03-16 帝國製薬株式会社 生理学的に活性なペプチドを含有する膣投与製剤
JP2500361B2 (ja) 1993-07-14 1996-05-29 工業技術院長 温熱感評価用感覚エレメント
DE4340781C3 (de) * 1993-11-30 2000-01-27 Novartis Ag Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung
JP3812957B2 (ja) * 1994-08-02 2006-08-23 森永乳業株式会社 角膜損傷治療剤
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
FR2733421B1 (fr) 1995-04-28 1997-06-06 Oreal Utilisation de derives de l'hormone stimulatrice des melanocytes de type alpha pour stimuler ou induire la pousse des cheveux et/ou stopper leur chute
US6001812A (en) 1995-04-28 1999-12-14 Societe L'oreal S.A. Modulating body/cranial hair growth with derivatives of the α-type melanocyte-stimulating hormone
FR2738746B1 (fr) 1995-09-19 1997-11-14 Oreal Utilisation d'au moins un peptide dans une composition cosmetique ou pour la preparation d'un medicament
FR2778558B1 (fr) 1998-05-12 2001-02-16 Oreal Utilisation d'inhibiteur de metalloproteinases pour induire et/ou stimuler la croissance des cheveux ou des poils et/ou freiner leur chute
FR2781157B1 (fr) 1998-07-15 2000-08-25 Oreal Composition anti-inflammatoire
FR2784028B1 (fr) 1998-10-01 2003-02-07 Oreal Utilisation d'un peptide prevenant les reactions d'intolerance de la peau, notamment dans des compositions cosmetiques
CA2359636A1 (en) 1999-01-22 2000-07-27 Andrew W. Taylor Activation of regulatory t cells by alpha-melanocyte stimulating hormone
US6803044B1 (en) * 1999-03-24 2004-10-12 Zengen, Inc. Antimicrobial and anti-inflammatory peptides for use in human immunodeficiency virus
US6887846B2 (en) 1999-03-24 2005-05-03 Zengen, Inc. Antimicrobial amino acid sequences derived from alpha-melanocyte-stimulating hormone
US6800291B1 (en) * 1999-03-24 2004-10-05 Zengen, Inc. Uro-genital condition treatment system
WO2000059527A1 (en) * 1999-03-24 2000-10-12 Zengen, Inc. Antimicrobial amino acid sequences derived from alpha-melanocyte-stimulating hormone
US7244710B2 (en) * 2002-05-21 2007-07-17 Zengen, Inc. Treatment of ophthalmic infections using antimicrobial peptides
US6780838B2 (en) 2001-01-29 2004-08-24 Zengen, Inc. Compounds for treating fungal pathologies of the oral cavity
US6894028B2 (en) * 2001-04-06 2005-05-17 Zengen, Inc. Use of KPV tripeptide for dermatological disorders
US7115574B2 (en) * 2001-12-10 2006-10-03 Zengen, Inc. System and method for support legacy operating system booting in a legacy-free system

Also Published As

Publication number Publication date
ZA200602144B (en) 2007-08-29
CR8341A (es) 2007-06-08
EP1667703A2 (en) 2006-06-14
CA2542303A1 (en) 2005-03-24
AU2004272049A1 (en) 2005-03-24
US7402559B2 (en) 2008-07-22
EP1667703A4 (en) 2009-07-29
CN1867349A (zh) 2006-11-22
JP2007505045A (ja) 2007-03-08
WO2005025503A3 (en) 2005-09-22
US20050037032A1 (en) 2005-02-17
WO2005025503A2 (en) 2005-03-24

Similar Documents

Publication Publication Date Title
ECSP066494A (es) Composición y método para tratamiento de condiciones uro-genitales
CR7614A (es) Preparaciones de insulina acida con estabilidad mejorada
AR048017A1 (es) Composicion y metodo para aumentar la biodisponibilidad
CY1123724T1 (el) Φαρμακευτικη συνθεση για τροποποιημενη αποδεσμευση
BRPI0407882A (pt) conjugados de polìmero-porção de fator viii
AR044926A1 (es) Sistema de suministro de farmacos gelificante in situ
BR0113757A (pt) Derivados de quinolinona como inibibores de tirosina quinase
MA27523A1 (fr) Formulation retard a liberation controlee
PE20081361A1 (es) Composiciones farmaceuticas de clonazepam y metodos de uso de las mismas
ES2570454T3 (es) Sistema de liberación controlada de morfina
EA200400154A1 (ru) Новые лекарственные формы замещенного бензимидазола и способ их применения
EA200870379A1 (ru) Фармацевтическая композиция с замедленным высвобождением на основе системы высвобождения, включающей кислоторастворимый полимер и ph-зависимый полимер
ATE238813T1 (de) Wirkstoffformulierungen mit verzögerter freisetzung
CY1109189T1 (el) Τοπικα συστηματα παροχης γελης για την θεραπευτικη αντιμετωπιση των διαταραχων δερματος
ATE359779T1 (de) Selbstemulgierende systeme zur abgabe von taxoiden
JP2009516687A (ja) ブプレノルフィンを含む薬学的組成物
BR0309138A (pt) Processo para a preparação de uma composição farmacêutica finamente auto-emulsionável
EA200800161A1 (ru) Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций
CN101420934B (zh) 用于使氧化不稳定的组合物稳定的方法
EA200301019A1 (ru) Доставляемая перорально фармацевтическая композиция, включающая препарат с низкой растворимостью в воде (ингибитор cox-2), растворитель, жирную кислоту и органический амин
ATE493973T1 (de) Irbesartan enthaltende pharmazeutische zusammensetzung
BR112012007791A2 (pt) método para reticulação de polímeros solúveis em água para uso em aplicação de poços
BR0215187A (pt) Composições farmacêuticas que compreendem uma ciclosporina, um tensoativo hidrofìlico e um tensoativo lipofìlico
ZA200501116B (en) Benzimidazole derivatives and their use as prodrugs of proton pump inhibitor
Silva et al. Potential Tuberculostatic Agents: Micelle‐Forming Copolymer Poly (ethylene glycol)‐Poly (aspartic acid) Prodrug with Isoniazid